



SomnoMed exceeds 250,000 patients

22nd October 2015, SomnoMed Limited (ASX:SOM) is proud to announce that it passed the milestone of having fitted over one quarter of a million patients with SomnoDent[®] devices since its inception. Of these approximately 140,000 patients reside in the US and Canada; 70,000 in Europe and 40,000 in the Australia-Pacific region. Whilst it took 7½ years to reach 180,000, it took only a further 16 months to exceed the 250,000 patients milestone.

“To have exceeded a quarter of a million patients is an important event in SomnoMed’s history,” said Dr. Peter Neustadt, Executive Chairman of SomnoMed. “It is not only a sign of the success of our treatment and the rapidly growing acceptance of our COAT[™] alternative to CPAP, it is a very important element in proving the medical history SomnoMed has created over the years. Over all these years and with an impressive patient pool, SomnoMed is proud that it has been able to provide an effective, safe and more patient friendly treatment of obstructive sleep apnea (OSA) than is otherwise available.”

Recent results using the SomnoDent DentiTrac[®] compliance system in Australia found that SomnoDent[®] patients are highly compliant. Using the CPAP definition of compliance (4 hours minimum per night on 21 nights per month) SomnoDent[®] compliance was 95% compared to a generally reported compliance of CPAP around 60-70%. On an all night/every night basis SomnoDent[®] compliance was 85% with an average of 7.2 hours of sleep per night.

“We believe that COAT[™] is clearly on its way to be accepted as a mainstream treatment for OSA in many highly developed countries, especially for mild and moderate patients. Even more importantly, it is a safe and comfortable treatment alternative for the huge pool of patients who simply can not or do not want to use CPAP,” said Dr. Neustadt.

Contact: Dr. Peter Neustadt – Executive Chairman and CEO, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592 - mobile

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent[®] is the most comfortable and effective design and treatment solution for over 250,000 patients in 26 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>